In our study, we stratified 46 nAMD patients into two cohorts based on the level of choroidal neovascularization (CNV) activity while they were receiving anti-VEGF intravitreal therapy (IVT, Methods, Fig. 1a). The gene discussed is VEGFA; the disease is choroidal neovascularization.